U.S., Europe, Japan Look to Speed Up Drug Reviews

+ See all authors and affiliations

Science  17 Mar 2000:
Vol. 287, Issue 5460, pp. 1958-1959
DOI: 10.1126/science.287.5460.1958

You are currently viewing the summary.

View Full Text


Drug companies are hoping to save time and money by submitting the same safety and efficacy data to regulators in each of the three leading global markets. This fall, if all goes well, officials from the United States, Europe, and Japan will agree on a common drug review application form in hope of speeding the delivery of new treatments and, perhaps, lowering the cost to consumers.

Related Content